Re-activation can result partly from improving antigen presentation by APCs, upregulation of HLA-I on tumor cells, and alleviating T cells’ inhibition after treatments such as radiotherapy, anti-EGFR mAbs/molecular agents, and anti-PD-1 immunotherapy (87, 88, 91, 98, 99). Here, EGFR is linked to neoplasm.